Pharmaceutical Business review

Impax Selects OmniComm To Conduct Phase III Study In Parkinson’s Disease

OmniComm has reported that Impax has selected its TrialMaster EDC solution for conducting a phase III study in patients with Parkinson’s Disease. Impax would use OmniComm’s TrialMaster EDC solution to capture and process the company’s clinical trial data.

Suneel Gupta, chief scientific officer for Impax, said: The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study.

Stephen Johnson, COO of OmniComm, said: We look forward to working with Impax to assist them in the fight to cure Parkinson’s disease. We are honored that after an extensive evaluation, OmniComm’s electronic data capture solution, TrialMaster, was chosen to capture and process their clinical trial data. TrialMaster will enable them to continue to make informed and strategic decisions that will be vital to their success as a company.